GEHC$74.89
Chart
Performance
Key Stats
AI GEHC Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyGE HealthCare Technologies Inc. (GEHC) presents a compelling investment case driven by strong fundamentals in the growing healthcare technology sector. While short-term technicals indicate some consolidation, the long-term thematic tailwinds are significant. Moderate valuation and solid profitability support a positive outlook.
Thematic
GEHC is well-positioned in the essential healthcare sector, benefiting from global demand for advanced medical diagnostics and patient monitoring. Emerging trends in personalized medicine and digital health offer further growth avenues.
Fundamental
GEHC demonstrates robust financial health with consistent revenue generation and improving profitability. The balance sheet is solid, and free cash flow generation is healthy, supporting its operations and potential shareholder returns.
Technical
The stock is trading within its 52-week range and shows mixed signals across different timeframes. While longer-term moving averages suggest an underlying bullish trend, short-term indicators indicate potential for sideways movement or minor pullbacks.
| Factor | Score |
|---|---|
| Healthcare Technology Demand | 85 |
| Digital Health & AI Integration | 75 |
| Aging Global Population | 80 |
| Regulatory Landscape | 65 |
| Competition | 60 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 70 |
| Growth | 50 |
| Balance Sheet Health | 70 |
| Cash Flow | 80 |
| Dividend Yield | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 70 |
| Support & Resistance | 75 |
| Volume Analysis | 60 |
| Short-Term Moving Averages | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent Earnings Surprises
The company has consistently beaten EPS estimates in the last 8 reported quarters, with an average surprise of 7.14%.
Attractive P/E Ratio
The current Price-to-Earnings (P/E) ratio of 16.13 is lower than the industry average of 20.5, suggesting the stock may be undervalued relative to its earnings.
Bearish Points (7)
Recent Underperformance
The stock has experienced a -13.69% decline over the last 6 months, suggesting potential headwinds or market concerns.
High Price-to-Sales Ratio
The TTM Price-to-Sales (P/S) ratio of 2.3 is higher than the 2024 P/S of 1.8, potentially indicating that recent revenue growth is not translating to a lower sales multiple.
Calendar
July 2025
25
Ex-Dividend Date
July 2025
30
Next Earnings Date
H: $0.96
A: $0.92
L: $0.85
H: 5.06B
A: 4.97B
L: 4.84B
August 2025
15
Next Dividend Date
Profile
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Seasonals
Price Target
87.96 USD
The 39 analysts offering 1 year price forecasts for GEHC have a max estimate of 110.00 and a min estimate of 73.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct global competitor in medical imaging, diagnostics, and advanced therapies, often challenging GEHC for market leadership.
Weight: 90
Key competitor in medical imaging, ultrasound, patient monitoring, and connected care solutions, with significant overlap in GEHC's core segments.
Weight: 88
Major global medical device company with a broad portfolio including surgical technologies, patient care solutions, and cardiovascular products, some direct and indirect competition.
Weight: 85
Diversified healthcare giant with a significant MedTech segment that competes in various medical device categories, including surgical, orthopedics, and vision care.